西藏药业 (600211.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	3.0B	3.0B	2.8B	3.1B	2.6B
Cost of Revenue	186.5M	172.5M	162.3M	155.1M	146.7M
Gross Profit	2.8B	2.8B	2.6B	3.0B	2.4B
Operating Expenses
R&D Expense	95.3M	74.1M	28.9M	17.4M	88.1M
SG&A Expense	—	—	—	—	—
General & Admin Expense	133.4M	129.2M	122.1M	124.0M	132.5M
Selling & Marketing Expense	1.7B	1.6B	1.6B	1.8B	1.4B
Other Expenses	—	—	—	—	—
Total Operating Expenses	1.9B	1.8B	1.7B	1.9B	1.7B
Cost and Expenses	2.1B	2.0B	1.9B	2.1B	1.8B
Operating Income (EBIT)	1.1B	1.0B	1.2B	899.1M	464.7M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	1.1B	1.0B	1.2B	898.2M	463.4M
Income Tax Expense	126.0M	123.6M	95.0M	87.9M	88.1M
Bottom Line
Net Income	967.4M	937.9M	1.1B	800.9M	369.8M
Earnings from Cont. Ops	929.6M	917.0M	1.1B	810.2M	375.3M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	967.4M	937.9M	1.1B	800.9M	369.8M
Per Share
Basic EPS	CN¥3.00	CN¥2.91	CN¥3.26	CN¥2.48	CN¥1.49
Diluted EPS	CN¥3.00	CN¥2.91	CN¥3.26	CN¥2.48	CN¥1.49
Revenue Per Share	CN¥9.32	CN¥9.25	CN¥8.70	CN¥9.71	CN¥10.29
Shares
Basic Shares Outstanding	321.2M	322.3M	322.5M	322.9M	248.2M
Diluted Shares Outstanding	321.2M	322.3M	322.5M	322.9M	248.2M
Profitability Metrics
EBITDA	—	1.1B	1.2B	968.2M	535.4M
D&A	—	80.4M	75.8M	69.1M	70.8M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026